Hologic (HOLX) Aktie Kurs
Hologic Kurs
De seneste 19 år voksede Hologics omsætning med 12,2 % årligt og nåede 4,10 Mrd. USD. Indtjening pr. aktie er vokset med 12,8 % om året de seneste 19 år. For Hologic er nettoavance på 13,8 % ned i forhold til 33,2 % for et par år siden. Konsensus 12-måneders kursmål for Hologic er 77,52 USD, cirka over kursen med 2,0 %. Af 23 analytikere anbefaler 0 køb — den samlede vurdering er Hold.
Hologic aktiekurs
Hent disse data via Eulerpool API
100.000 requests/md. gratis · intet kreditkort
Hologic aktie og aktieanalyse
Hyppigt stillede spørgsmål om Hologic-aktien
The main competitors of Hologic Inc in the market include companies like Abbott Laboratories, Thermo Fisher Scientific, and Becton, Dickinson and Company.
The business model of Hologic Inc revolves around providing innovative diagnostic solutions, primarily focused on women's healthcare. Hologic develops and markets a wide range of medical devices and instruments, including imaging systems, surgical products, and molecular diagnostic assays. The company's products are designed to enable healthcare professionals to effectively screen, diagnose, and treat various conditions and diseases. Hologic is renowned for its advanced technologies in breast health, gynecology, and skeletal health, offering solutions that empower early detection and intervention. By constantly pushing the boundaries of medical technology, Hologic Inc remains committed to improving healthcare outcomes for women around the world.
Hologic Inc is primarily active in the healthcare industry, specifically in the field of diagnostic products and medical devices. With a focus on improving women's health, Hologic Inc develops and manufactures a wide range of innovative solutions. Their portfolio includes advanced imaging systems, molecular diagnostic assays, surgical instruments, and women's health screening tests. As a prominent player in the healthcare sector, Hologic Inc constantly strives to provide cutting-edge technologies and solutions to address various medical challenges.
Hologic Inc is a leading global healthcare and diagnostics company. Established in 1985, Hologic has excelled in providing innovative solutions for women's health, with a focus on early detection and treatment of breast and cervical cancers. The company's dedication to research and development has resulted in breakthrough technologies, including the introduction of the first 3D mammography system. Hologic has expanded its portfolio to include diagnostics, surgical and skeletal health, and GYN surgical products. With a strong commitment to advancing healthcare, Hologic Inc continues to make significant contributions to improving patient outcomes and quality of life.
Hologic Inc, a leading healthcare company, has achieved several significant milestones. In recent years, the company has made notable advancements in breast health solutions. They introduced the world's first 3D mammography system, which revolutionized breast cancer detection by providing clearer and more accurate images. Hologic Inc also developed the Genius™ 3D Mammography™ exam, proven to detect breast cancer at an earlier stage compared to 2D mammography alone. Furthermore, the company expanded its portfolio by acquiring Gen-Probe, a molecular diagnostics company, allowing Hologic Inc to offer a comprehensive range of diagnostic solutions. These milestones highlight Hologic Inc's commitment to innovation and improving women's healthcare outcomes.
Hologic Inc is primarily present in various countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered. Additionally, Hologic Inc operates in Europe, including countries like Germany, France, Italy, and the United Kingdom. It also has a presence in Asia, particularly in countries such as China and Japan. Furthermore, Hologic Inc serves customers in Canada and Latin America, with a focus on countries like Mexico and Brazil. Overall, Hologic Inc has a global reach and aims to provide its products and services to diverse markets internationally.
Hologic Inc represents values of innovation, commitment to quality, and patient-centric approach. The corporate philosophy of Hologic Inc revolves around developing cutting-edge medical technologies to improve women's health outcomes. With a focus on providing accurate and reliable diagnostic solutions, Hologic Inc strives to empower healthcare professionals and patients alike. The company's dedication to research and development, evidence-based practices, and collaboration with healthcare experts reinforces its commitment to advancing healthcare for women globally. Hologic Inc's mission is to make a difference in people's lives through advanced healthcare solutions, making them a trusted and reliable leader in the industry.
Analytikere sætter i øjeblikket et gennemsnitligt kursmål på 76,66 USD for Hologic-aktien (median: 77,52 USD), svarende til +0,9 % i forhold til seneste kurs. Konsensus bygger på 23 analytikervurderinger.
23 analytikere vurderer i øjeblikket Hologic-aktien: 0 anbefaler køb, 20 hold og 3 salg. For 2026 forventer analytikere, at Hologic genererer omsætning på 4,24 Mrd. USD og indtjening pr. aktie på 4,49 USD.
Omregnet til den aktuelle valutakurs handles Hologic-aktien til 67,71 EUR (76,01 USD).
Hologic-aktien (HOLX) er noteret på 9 børser, herunder: NASDAQ (HOLX), London (0J5Q.L), SIX (Zürich) (HO1.SW), XETRA (HO1.DE), Frankfurt (HO1.F), München (HO1.MU), Düsseldorf (HO1.DU), Wien (HOLX.VI).
Hologic Inc is an international leading provider of medical technology products and solutions. The company, headquartered in Marlborough, Massachusetts, operates globally and is divided into four business segments: Diagnostics, Gynecology, Skeletal Health, and Aesthetics.
forventet-omsætningen for Hologic er 4,24 Mrd. USD. Dette tal er baseret på aktuelle finansielle data og afspejler virksomhedens forretningsydeevne.
forventet-overskuddet for Hologic er 1,01 Mrd. USD. Nettooverskuddet afspejler virksomhedens rentabilitet efter fradrag af alle udgifter.
Pris-til-indtjening-forholdet (P/E) for Hologic er i øjeblikket 16,93. P/E-forholdet sammenligner den nuværende aktiekurs med indtjeningen pr. aktie og hjælper investorer med at vurdere værdiansættelsen af Hologic-aktien.
Pris-til-salgs-forholdet (P/S) for Hologic er i øjeblikket 4,05. P/S-forholdet sammenligner markedskapitalisering med årlig omsætning og fungerer som en værdiansættelsesmetrik for Hologic-aktien.
AlleAktien-kvalitetsscore for Hologic er 1/10.
ISIN for Hologic er US4364401012. ISIN (International Securities Identification Number) er en globalt unik identifikator for værdipapirer.
WKN for Hologic er 879100. WKN (Wertpapierkennnummer) er et seks-cifret tysk identifikationsnummer for værdipapirer.
Tickeren for Hologic er HOLX. Tickersymbolet bruges til at handle Hologic-aktier på børsen.
Hologic aktie
Hologic Peer Group
Hologic Ticker
Hologic FIGI
Alle fundamentale data om Hologic i deep dive
Vores aktieanalyse af Hologic-aktien indeholder vigtige finansielle nøgletal som omsætning, profit, P/E-ratioen, P/S-ratioen, EBIT samt informationer om udbytte. Desuden ser vi på aspekter som aktier, markedskapitalisering, gæld, egenkapital og forpligtelser hos Hologic. Hvis du søger mere detaljerede oplysninger om disse emner, tilbyder vi på vores undersider omfattende analyser: